Sujet(s)
Sténose aortique , Valve aortique , Prothèse valvulaire cardiaque , Remplacement valvulaire aortique par cathéter , Humains , Remplacement valvulaire aortique par cathéter/instrumentation , Remplacement valvulaire aortique par cathéter/méthodes , Sténose aortique/chirurgie , Résultat thérapeutique , Valve aortique/chirurgie , Valve aortique/imagerie diagnostique , Mâle , Femelle , Sujet âgé de 80 ans ou plus , Sujet âgé , Conception de prothèseRÉSUMÉ
BACKGROUND: Aortic stenosis (AS) and mitral regurgitation (MR) result in different patterns of left ventricular remodeling and hypertrophy. OBJECTIVES: We characterized left ventricular wall stress (LVWS) profiles in pressure and volume-overloaded systems, examined the relationship between baseline LVWS and cardiac remodeling, and assessed the acute effects of valve intervention on LVWS using invasive pressures combined with cardiac magnetic resonance (CMR) imaging measures of left ventricular volumes/mass. METHODS: A total of 47 patients with severe AS undergoing transcatheter aortic valve replacement (TAVR) and 15 patients with severe MR undergoing MitraClip (MC) underwent a 6-minute walk test (6MWT), transthoracic echocardiogram, and CMR before their procedures. Catheters in the left ventricle were used to record hemodynamic changes before and after valve/clip deployment. This was integrated with CMR data to calculate LVWS before and after intervention. RESULTS: The TAVR group demonstrated significant reductions in systolic LVWS post procedure (median 24.7 Pa [IQR: 14 Pa] pre vs median 17.3 Pa [IQR: 12 Pa] post; P < 0.001). The MC group demonstrated significant reductions in diastolic LVWS (median 6.4 Pa [IQR: 5 Pa] pre vs median 4.3 Pa [IQR: 4.1 Pa] post; P = 0.021) with no significant change in systolic LVWS (30.6 ±1.61 pre vs 33 ±2.47 Pa post; P = 0.16). There was an inverse correlation between baseline systolic LVWS and 6MWT in the TAVR group (r = -0.31; P = 0.04). CONCLUSIONS: TAVR results in significant reductions in systolic LVWS acutely. MC results in significant reductions in diastolic LVWS. Higher baseline systolic LVWS in TAVR is associated with shorter 6MWT suggesting that in AS, LVWS may be a useful marker of early decompensation.
Sujet(s)
Sténose aortique , Insuffisance mitrale , Remplacement valvulaire aortique par cathéter , Remodelage ventriculaire , Humains , Mâle , Femelle , Remplacement valvulaire aortique par cathéter/méthodes , Sténose aortique/chirurgie , Sténose aortique/physiopathologie , Sténose aortique/imagerie diagnostique , Sujet âgé , Remodelage ventriculaire/physiologie , Insuffisance mitrale/chirurgie , Insuffisance mitrale/physiopathologie , Insuffisance mitrale/imagerie diagnostique , Sujet âgé de 80 ans ou plus , IRM dynamique/méthodes , Échocardiographie , Ventricules cardiaques/imagerie diagnostique , Ventricules cardiaques/physiopathologieRÉSUMÉ
OBJECTIVE: This study aimed to compare hemodynamic performances and clinical outcomes of patients with small aortic annulus (SAA) who underwent aortic valve replacement by means of sutureless aortic valve replacement (SUAVR) or transcatheter aortic valve implantation (TAVI). METHODS: From 2015 to 2020, 622 consecutive patients with SAA underwent either SUAVR or TAVI. Through a 1:1 propensity score matching analysis, two homogeneous groups of 146 patients were formed. Primary endpoint: all cause-death at 36 months. Secondary endpoints: incidence of moderate to severe patient-prosthesis mismatch (PPM) and incidence of major adverse cardiovascular and cerebrovascular events (MACCEs). RESULTS: All-cause death at three years was higher in the TAVI group (SUAVR 12.2% vs. TAVI 21.0%, P=0.058). Perioperatively, comparable hemodynamic performances were recorded in terms of indexed effective orifice area (SUAVR 1.12 ± 0.23 cm2/m2 vs. TAVI 1.17 ± 0.28 cm2/m2, P=0.265), mean transvalvular gradients (SUAVR 12.9 ± 5.3 mmHg vs. TAVI 12.2 ± 6.2 mmHg, P=0.332), and moderate-to-severe PPM (SUAVR 4.1% vs. TAVI 8.9%, P=0.096). TAVI group showed a higher cumulative incidence of MACCEs at 36 months (SUAVR 18.1% vs. TAVI 32.6%, P<0.001). Pacemaker implantation (PMI) and perivalvular leak ≥ 2 were significantly higher in TAVI group and identified as independent predictors of mortality (PMI: hazard ratio [HR] 3.05, 95% confidence interval [CI] 1.34-6.94, P=0.008; PPM: HR 2.72, 95% CI 1.25-5.94, P=0.012). CONCLUSION: In patients with SAA, SUAVR and TAVI showed comparable hemodynamic performances. Moreover, all-cause death and incidence of MACCEs at follow-up were significantly higher in TAVI group.
Sujet(s)
Sténose aortique , Valve aortique , Hémodynamique , Score de propension , Remplacement valvulaire aortique par cathéter , Humains , Remplacement valvulaire aortique par cathéter/méthodes , Remplacement valvulaire aortique par cathéter/mortalité , Remplacement valvulaire aortique par cathéter/effets indésirables , Mâle , Femelle , Hémodynamique/physiologie , Sujet âgé , Sujet âgé de 80 ans ou plus , Valve aortique/chirurgie , Sténose aortique/chirurgie , Sténose aortique/mortalité , Résultat thérapeutique , Interventions chirurgicales sans suture/méthodes , Prothèse valvulaire cardiaque , Études rétrospectives , Complications postopératoires , Implantation de valve prothétique cardiaque/méthodes , Facteurs de risqueRÉSUMÉ
OBJECTIVE: To compare long-term cardiovascular (CV) outcomes between men and women with aortic stenosis (AS) undergoing aortic valve replacement (AVR) by the type of valve implant. METHODS: The study population consisted of 14 123 non-selected patients with AS undergoing first-time AVR and included in the Swedish Web system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART) registry during 2008-2016. Comparisons were made between men and women and type of valve implant (ie, surgical implantation with a mechanical (mSAVR) (n=1 966) or biological valve (bioSAVR) (n=9 801)) or by a transcatheter approach (TAVR) (n=2 356). Outcomes included all-cause mortality, ischaemic stroke, major bleeding, thromboembolic events, heart failure and myocardial infarction, continuously adjusted for significant comorbidities and medical treatment. RESULTS: In the mSAVR cohort, there were no significant sex differences in any CV events. In the bioSAVR cohort, a higher risk of death (HR: 1.14; 95% CI: 1.04 to 1.26, p=0.007) and major bleeding (HR: 1.41; 95% CI: 1.18 to 1.69, p<0.001) was observed in men. In the TAVR cohort, men suffered a higher risk of death (HR: 1.24; 95% CI: 1.07 to 1.45, p=0.005), major bleeding (HR: 1.35; 95% CI: 1.00 to 1.82, p=0.022) and thromboembolism (HR: 1.35, 95% CI: 1.00 to 1.82, p=0.047). CONCLUSION: No significant long-term difference in CV events was noted between men and women undergoing AVR with a mechanical aortic valve. In both the bioSAVR and TAVR cohort, mortality was higher in men who also had an increased incidence of several other CV events.
Sujet(s)
Sténose aortique , Valve aortique , Implantation de valve prothétique cardiaque , Enregistrements , Humains , Sténose aortique/chirurgie , Sténose aortique/mortalité , Mâle , Femelle , Suède/épidémiologie , Sujet âgé , Facteurs sexuels , Sujet âgé de 80 ans ou plus , Facteurs de risque , Valve aortique/chirurgie , Valve aortique/imagerie diagnostique , Implantation de valve prothétique cardiaque/effets indésirables , Implantation de valve prothétique cardiaque/méthodes , Résultat thérapeutique , Appréciation des risques/méthodes , Remplacement valvulaire aortique par cathéter/effets indésirables , Remplacement valvulaire aortique par cathéter/méthodes , Remplacement valvulaire aortique par cathéter/mortalité , Prothèse valvulaire cardiaque , Facteurs temps , Études de suivi , Pronostic , Complications postopératoires/épidémiologie , Complications postopératoires/mortalité , Incidence , Taux de survie/tendances , Études rétrospectivesRÉSUMÉ
INTRODUCTION: Over the past two decades, transcatheter aortic valve replacement (TAVR) has expanded its application across all surgical risk levels, including low-risk patients, where, due to longer life expectancy, reducing common pitfalls of TAVR is essential. To address these needs, many technological advancements have been developed. Myval and the new generation Myval Octacor (Meril Life Sciences Pvt. Ltd) are novel balloon-expandable (BE) transcatheter heart valve (THV) systems designed for the treatment of severe aortic stenosis. AREAS COVERED: This review aims to illustrate the design features of these novel THVs and the main evidence from available studies. Furthermore, we provide evidence of these THVs' performance in challenging scenarios such as extra-large aortic annuli, bicuspid aortic valves, and valve-in-valve/valve-in-ring procedures. EXPERT OPINION: Myval and Myval Octacor have demonstrated comparable early safety and clinical efficacy to the leading contemporary THVs, exhibiting remarkably low rates of moderate to severe paravalvular leak (PVL) and permanent pacemaker implantation (PPI). The wide range of sizes offered by the Myval family may minimize the risk of under-/oversizing, potentially explaining the lower rates of the aforementioned phenomena. Moreover, the presence of both internal skirt and external reinforced cuff may also explain the low rate of moderate to severe PVL.
Sujet(s)
Sténose aortique , Bioprothèse , Prothèse valvulaire cardiaque , Conception de prothèse , Remplacement valvulaire aortique par cathéter , Humains , Remplacement valvulaire aortique par cathéter/méthodes , Remplacement valvulaire aortique par cathéter/effets indésirables , Sténose aortique/chirurgie , Indice de gravité de la maladie , Valve aortique/chirurgie , Valve aortique/imagerie diagnostiqueRÉSUMÉ
BACKGROUND: Transcatheter aortic valve implantation (TAVI) has been increasingly used in patients with severe aortic stenosis (AS). Since coronary artery disease (CAD) is common among these patients, it is crucial to choose the best method and timing of revascularization. This study aims to compare different timing strategies of percutaneous coronary intervention (PCI) in patients with severe AS undergoing TAVI to clarify whether PCI timing affects the patients' outcomes or not. METHODS: A frequentist network meta-analysis was conducted comparing three different revascularization strategies in patients with CAD undergoing TAVI. The 30-day all-cause mortality, in-hospital mortality, all-cause mortality at 1 year, 30-day rates of myocardial infarction (MI), stroke, and major bleeding, and the need for pacemaker implantation at 6 months were analyzed in this study. RESULTS: Our meta-analysis revealed that PCI during TAVI had higher 30-day mortality (RR = 2.46, 95% CI = 1.40-4.32) and in-hospital mortality (RR = 1.70, 95% CI = [1.08-2.69]) compared to no PCI. Post-TAVI PCI was associated with higher 1-year mortality compared to other strategies. While no significant differences in major bleeding or stroke were observed, PCI during TAVI versus no PCI (RR = 3.63, 95% CI = 1.27-10.43) showed a higher rate of 30-day MI. CONCLUSION: Our findings suggest that among patients with severe AS and CAD undergoing TAVI, PCI concomitantly with TAVI seems to be associated with worse 30-day outcomes compared with no PCI. PCI after TAVI demonstrated an increased risk of 1-year mortality compared to alternative strategies. Choosing a timing strategy should be individualized based on patient characteristics and procedural considerations.
Sujet(s)
Sténose aortique , Méta-analyse en réseau , Intervention coronarienne percutanée , Remplacement valvulaire aortique par cathéter , Humains , Sténose aortique/chirurgie , Sténose aortique/mortalité , Remplacement valvulaire aortique par cathéter/effets indésirables , Remplacement valvulaire aortique par cathéter/méthodes , Intervention coronarienne percutanée/méthodes , Intervention coronarienne percutanée/effets indésirables , Facteurs de risque , Mortalité hospitalière , Résultat thérapeutique , Facteurs temps , Maladie des artères coronaires/mortalité , Maladie des artères coronaires/thérapie , Maladie des artères coronaires/complications , Maladie des artères coronaires/chirurgie , Appréciation des risques/méthodes , Indice de gravité de la maladieRÉSUMÉ
OBJECTIVES: Aortic valved allografts (homografts) have been used alternatively to mechanical or biological valve prostheses in expectation of better durability; however, homograft valves do degenerate, and redo procedures have proven challenging due to heavy wall calcification. The aim of the study was to compare the outcome of open surgical (SAVR) and transcatheter aortic valve replacement (TAVR) in degenerated homografts. METHODS: Between 1993 and 2022, 81 patients underwent repeat aortic valve procedures having previously received an aortic homograft. The redo had become necessary due to regurgitation in 85% and stenosis in 15%. Sixty-five percent underwent open surgery, 35% TAVR. RESULTS: Isolated SAVR was possible in 79%, and root procedures were necessary in 21%. TAVR was performed in 79% via transfemoral and 21% via transapical access. Median prosthetic valve size was 23 (22.3-23.2) mm in the SAVR and 26 (25.2-26.9) in the TAVR group. Thirty-day mortality was 0% in the TAVR and 7% in the SAVR group (P = n.s.). TAVR showed a significantly better outcome concerning prolonged ventilation (0 vs 21%, P = 0.013) as well as ICU (1 vs 2 days; P < 0.001) and in-hospital stay (10.5 vs 13 days; P = 0.028). Five-year survival was statistically comparable between groups, and no severe leakage was observed. CONCLUSIONS: SAVR following structural homograft degeneration shows acceptable results, but the perioperative risk remains substantial and poorly predictable. TAVR presents a reasonable and more easily accessible alternative and is associated with good short- and mid-term results. In the absence of relevant contraindications, TAVR is presently the preferred treatment option for these patients at our center.
Sujet(s)
Valve aortique , Prothèse valvulaire cardiaque , Réintervention , Remplacement valvulaire aortique par cathéter , Humains , Mâle , Femelle , Valve aortique/chirurgie , Sujet âgé , Remplacement valvulaire aortique par cathéter/méthodes , Réintervention/statistiques et données numériques , Sujet âgé de 80 ans ou plus , Sténose aortique/chirurgie , Allogreffes , Implantation de valve prothétique cardiaque/méthodes , Implantation de valve prothétique cardiaque/statistiques et données numériques , Défaillance de prothèse , Résultat thérapeutique , Études rétrospectives , Bioprothèse , Adulte d'âge moyenRÉSUMÉ
The bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction (BASILICA) procedure allows patients with severe aortic stenosis and anatomical challenges from aortic leaflet orientation, positioning of coronary ostia, and height of sinuses of Valsalva to undergo TAVR. We present a case of intraprocedural cardiac arrest secondary to iatrogenic left main coronary artery obstruction following a successful BASILICA procedure.
Sujet(s)
Sténose aortique , Arrêt cardiaque , Remplacement valvulaire aortique par cathéter , Humains , Remplacement valvulaire aortique par cathéter/effets indésirables , Remplacement valvulaire aortique par cathéter/méthodes , Sténose aortique/chirurgie , Arrêt cardiaque/étiologie , Sujet âgé de 80 ans ou plus , Maladie iatrogène/prévention et contrôle , Mâle , Complications peropératoires/étiologie , Complications peropératoires/prévention et contrôle , Bioprothèse/effets indésirables , Femelle , CoronarographieRÉSUMÉ
BACKGROUND: Compared to traditional thoracotomy, transapical transcatheter aortic valve implantation (TAVI) surgery offers reduced trauma and faster recovery, fostering the adoption of enhanced recovery after surgery (ERAS) protocols in cardiac surgery. Despite these advancements, postoperative pain management has received insufficient attention. The potential effects of multi-mode analgesia, including ultrasound-guided serratus anterior plane block (SAPB), on postoperative pain and early quality of recovery have not been widely studied, lacking comprehensive prospective evidence. Therefore, this study aims to investigate the impact of SAPB combined with general anesthesia on early recovery quality and analgesic efficacy in transapical TAVI patients. METHODS: This prospective, randomized controlled study will enroll 70 patients undergoing transapical TAVI, randomly allocated to either the SAPB group or the control group. The primary outcome, assessed using Quality of Recovery-40 (QOR-40) scale, focuses on the quality of recovery at 24 h and 48 h postoperatively. Secondary outcomes include the visual analog scale (VAS) pain scores at rest and during coughing at 6 h, 12 h, 24 h, and 48 h after surgery, frequency of patient-controlled analgesia (PCA) utilization at 24 h and 48 h, opioid consumption at 24 h and 48 h, time and frequency of rescue analgesia and severe pain at 24 h and 48 h, incidence of nausea and vomiting at 48 h after surgery, and dosage of antiemetic drugs. DISCUSSION: The purpose of our study is to evaluate the effects of ultrasound-guided SAPB combined with general anesthesia on postoperative early quality of recovery and analgesia in transapical TAVI patients. The results obtained may provide valuable insight for the implementation of multi-mode analgesia and enhanced ERAS in this specific patient population. TRIAL REGISTRATION: China Clinical Trial Register ChiCTR2300068584. Registered on 24 February 2023.
Sujet(s)
Anesthésie générale , Bloc nerveux , Douleur postopératoire , Remplacement valvulaire aortique par cathéter , Échographie interventionnelle , Humains , Douleur postopératoire/étiologie , Douleur postopératoire/prévention et contrôle , Douleur postopératoire/diagnostic , Bloc nerveux/méthodes , Remplacement valvulaire aortique par cathéter/méthodes , Remplacement valvulaire aortique par cathéter/effets indésirables , Études prospectives , Essais contrôlés randomisés comme sujet , Résultat thérapeutique , Analgésie autocontrôlée/méthodes , Récupération fonctionnelle , Mâle , Femelle , Facteurs temps , Mesure de la douleur , Sujet âgé , Chine , Gestion de la douleur/méthodesRÉSUMÉ
BACKGROUND: Transcatheter aortic valve replacement (TAVR) has increased in utilization since its approval for management of aortic stenosis patients across all risk strata. We report a rare case of aortic valve leaflet avulsion after balloon expandable TAVR managed with urgent surgery. CASE PRESENTATION: A 78-year-old male underwent TAVR complicated by avulsion of the native aortic valve leaflet's left coronary cusp. He was taken for urgent surgery for cusp resection to prevent thromboembolic complications. CONCLUSIONS: Native aortic valve leaflet avulsion should be suspected during TAVR in instances of extreme hemodynamic instability after balloon aortic valvuloplasty. As TAVR expands in lower risk patients, surgeons should have a low threshold to intervene surgically to treat native leaflet avulsion or other complications.
Sujet(s)
Sténose aortique , Valve aortique , Remplacement valvulaire aortique par cathéter , Humains , Mâle , Sujet âgé , Remplacement valvulaire aortique par cathéter/méthodes , Sténose aortique/chirurgie , Valve aortique/chirurgie , Valve aortique/traumatismesSujet(s)
Sténose aortique , Remplacement valvulaire aortique par cathéter , Humains , Remplacement valvulaire aortique par cathéter/méthodes , Incidence , Sténose aortique/chirurgie , Mâle , Femelle , Conversion en chirurgie ouverte/statistiques et données numériques , Sujet âgé de 80 ans ou plus , Résultat thérapeutique , Sujet âgé , Études rétrospectives , UrgencesRÉSUMÉ
BACKGROUND: Using three-dimensional (3D) modalities for optimal pre-procedure planning in transcatheter aortic valve replacement (TAVR) is critical for procedural success. However, current methods rely on visualizing images on a two-dimensional screen, using shading and colors to create the illusion of 3D, potentially impeding the accurate comprehension of the actual anatomy structures. In contrast, a new Mixed Reality (MxR) based software enables accurate 3D visualization, imaging manipulation, and quantification of measurements. AIMS: The study aims to evaluate the feasibility, reproducibility, and accuracy of dimensions of the aortic valve complex as measured with a new holographic MxR software (ARTICOR®, Artiness srl, Milano, Italy) compared to a widely used software for pre-operative sizing and planning (3mensio Medical Imaging BV, Bilthoven, The Netherlands). METHODS: This retrospective, observational, double-center study enrolled 100 patients with severe aortic stenosis who underwent cardiac computed tomography (CCT) before TAVR. The CCT datasets of volumetric aortic valve images were analyzed using 3Mensio and newly introduced MxR-based software. RESULTS: Ninety-eight percent of the CCT datasets were successfully converted into holographic models. A higher level of agreement between the two software systems was observed for linear metrics (short, long, and average diameter). In comparison, agreement was lower for area, perimeter, and annulus-to-coronary ostia distance measurements. Notably, the annulus area, annular perimeter, left ventricular outflow tract (LVOT) area, and LVOT perimeter were significantly and consistently smaller with the MxR-based software compared to the 3Mensio. Excellent interobserver reliability was demonstrated for most measurements, especially for direct linear measurements. CONCLUSIONS: Linear measurements of the aortic valve complex using MxR-based software are reproducible compared to the standard CCT dataset analyzed with 3Mensio. MxR-based software could represent an accurate tool for the pre-procedural planning of TAVR.
Sujet(s)
Sténose aortique , Holographie , Remplacement valvulaire aortique par cathéter , Remplacement valvulaire aortique par cathéter/méthodes , Humains , Études rétrospectives , Holographie/méthodes , Femelle , Sténose aortique/chirurgie , Sténose aortique/imagerie diagnostique , Mâle , Sujet âgé de 80 ans ou plus , Sujet âgé , Imagerie tridimensionnelle/méthodes , Valve aortique/chirurgie , Valve aortique/imagerie diagnostique , Reproductibilité des résultats , Réalité augmentée , LogicielSujet(s)
Sténose aortique , Valve aortique , Essais contrôlés randomisés comme sujet , Remplacement valvulaire aortique par cathéter , Humains , Valve aortique/chirurgie , Remplacement valvulaire aortique par cathéter/méthodes , Sténose aortique/chirurgie , Mâle , Implantation de valve prothétique cardiaque/méthodes , Femelle , Estimation de Kaplan-Meier , Taux de survie/tendances , Facteurs temps , Sujet âgé , Facteurs de risque , Résultat thérapeutiqueRÉSUMÉ
INTRODUCTION: Oslo University Hospital is a tertiary center conducting a significant number of transcatheter aortic valve implantation (TAVI) procedures per year. In this follow-up MediPace study, we aimed to investigate early echocardiographic changes in systolic and diastolic functions after TAVI in these patients. METHODS: All patients enrolled in the previous study were contacted 3 months after TAVI for echocardiographic evaluation. Detailed echocardiography was performed 3.5 ± 1.6 months after TAVI, and compared with baseline evaluations. RESULTS: A total of 101 patients were analyzed. Mean age was 80.1 ± 6.8 years and 40% of the patients were female. We observed a significant improvement in global longitudinal strain (GLS) (pre-TAVI -16.8 ± 4.1%, post-TAVI -17.8 ± 3.6%, p < .001), with no notable change in LVEF. More than half of the patients (52%) experienced a significant reverse remodeling with ≥10% decrease in left ventricular mass index (LVMi) following TAVI (pre-TAVI 123.6 ± 32.1 vs. 109.7 ± 28.9 g/m2 post-TAVI, p < .001). Pre-TAVI LVMi was a positive predictor, whereas history of HT was a negative predictor of LVMi reduction. There was no significant improvement in diastolic function following TAVI. Highest degree of paravalvular leakage was mild to moderate and was observed in only 2%. CONCLUSIONS: A significant improvement in GLS and LVMi was found following TAVI. History of hypertension and baseline LVMi were predictors of LVMi change. There was no notable change in diastolic function, including left atrial strain.
Sujet(s)
Sténose aortique , Échocardiographie , Remplacement valvulaire aortique par cathéter , Remodelage ventriculaire , Humains , Femelle , Remplacement valvulaire aortique par cathéter/méthodes , Mâle , Sujet âgé de 80 ans ou plus , Échocardiographie/méthodes , Sténose aortique/chirurgie , Sténose aortique/physiopathologie , Remodelage ventriculaire/physiologie , Études de suivi , Résultat thérapeutique , Valve aortique/chirurgie , Valve aortique/imagerie diagnostiqueRÉSUMÉ
Repositionable self-expanding valves allow for repositioning during deployment to achieve optimal valve placement. However, the risk of brain injury associated with repositioning, as detected by diffusion-weighted magnetic resonance imaging (DW-MRI), is unknown. Consecutive patients undergoing transcatheter aortic valve replacement (TAVR) with repositionable self-expanding valves and receiving DW-MRI before and within 7 days post-TAVR procedure were included. The primary outcomes were incidence, number, total volume, and volume per lesion of the cerebral ischemic lesion in DW-MRI after TAVR. Univariate and multivariate logistic regression assessed the association between repositioning and bigger total lesion volume (> 1 cm3 or > 0.5 cm3). Negative binomial regressions were performed to explore the association between repositioning and number of lesions. A propensity score matching was performed to adjust the potential confounders. Moreover, inverse probability of treatment weighted regression model with nonstabilized weights was used as sensitivity analysis. Among 243 included patients, repositioning was performed in 116 (47.7%) patients. The incidence of overt stroke (1.7% vs. 1.6%, p = 0.927) and silent stroke (86.2% vs. 85.8%, p = 0.932) were comparable between two groups. However, the number of new lesions (5.0 [2.0-9.0] vs. 3.0 [2.0-6.0], p = 0.048), and total lesion volume (275.0 [90.0-947.5] mm3 vs. 180.0 [50.0-440.0] mm3, p = 0.022) were significantly higher in the repositioned group. Moreover, the proportion of patients with lesion size greater than 0.5 cm3 was higher in the repositioned group (37.9% vs. 22.0%, p = 0.007). The similar results were observed after propensity score matching. In both multivariate regression model and sensitivity analysis, the repositioning was the independent predictor of number of lesions and bigger total lesion volume after TAVR. The utilization of the repositioning feature may increase the number and volume of silent brain infarcts in DW-MRI in patients who underwent TAVR. (Transcatheter Aortic Valve Replacement Single Center Registry in Chinese Population [TORCH]; NCT02803294).
Sujet(s)
Lésions encéphaliques , Remplacement valvulaire aortique par cathéter , Sujet âgé , Sujet âgé de 80 ans ou plus , Femelle , Humains , Mâle , Valve aortique/chirurgie , Valve aortique/imagerie diagnostique , Valve aortique/anatomopathologie , Sténose aortique/chirurgie , Lésions encéphaliques/étiologie , Lésions encéphaliques/imagerie diagnostique , Imagerie par résonance magnétique de diffusion , Prothèse valvulaire cardiaque/effets indésirables , Incidence , Facteurs de risque , Accident vasculaire cérébral/étiologie , Remplacement valvulaire aortique par cathéter/effets indésirables , Remplacement valvulaire aortique par cathéter/méthodesRÉSUMÉ
BACKGROUND: Detailed visualization and precise measurements of aortic valve dimensions are critical for the success of transcatheter aortic valve implantation and for the prevention of complications. Currently, multislice computed tomography is the gold standard for assessment of the aortic annulus and surrounding structures to determine the prosthesis size. New technologies such as virtual reality (VR) not only enable 3-dimensional (3D) visualization with the potential to improve understanding of anatomy and pathology but also allow measurements in 3D. This study aims to investigate the feasibility, accuracy, and reproducibility of VR for the visualization of the aortic valve, the surrounding structures, and its role in preprocedural sizing for transcatheter aortic valve implantation. METHODS AND RESULTS: Based on the preprocedural multislice computed tomography data, 3mensio measurements and 3D visualizations and measurements using VR software were performed retrospectively on 60 consecutive patients who underwent transcatheter aortic valve implantation at our heart center. There were no significant differences but strong correlations between the VR measurements compared with those performed with the 3mensio software. Furthermore, excellent or good intra- and interobserver reliability could be demonstrated for all values. In a structured questionnaire, users reported that VR simplified anatomical understanding, improved 3D comprehension of adjacent structures, and was associated with very good self-perceived depth perception. CONCLUSIONS: The use of VR for preprocedural transcatheter aortic valve implantation sizing is feasible and has precise and reproducible measurements. In addition, 3D visualization improves anatomical understanding and orientation. To evaluate the potential benefits of 3D visualization for planning further cardiovascular interventions, research in this field is needed.
Sujet(s)
Sténose aortique , Valve aortique , Études de faisabilité , Prothèse valvulaire cardiaque , Imagerie tridimensionnelle , Tomodensitométrie multidétecteurs , Remplacement valvulaire aortique par cathéter , Réalité de synthèse , Humains , Valve aortique/imagerie diagnostique , Valve aortique/chirurgie , Reproductibilité des résultats , Mâle , Femelle , Remplacement valvulaire aortique par cathéter/méthodes , Remplacement valvulaire aortique par cathéter/instrumentation , Sujet âgé de 80 ans ou plus , Sujet âgé , Études rétrospectives , Sténose aortique/chirurgie , Sténose aortique/imagerie diagnostique , Conception de prothèse , Biais de l'observateur , Valeur prédictive des tests , Interprétation d'images radiographiques assistée par ordinateurSujet(s)
Sténose aortique , Implantation de valve prothétique cardiaque , Remplacement valvulaire aortique par cathéter , Humains , Remplacement valvulaire aortique par cathéter/méthodes , Implantation de valve prothétique cardiaque/méthodes , Sténose aortique/chirurgie , Résultat thérapeutique , Valve aortique/chirurgie , Prothèse valvulaire cardiaqueSujet(s)
Valve aortique , Bioprothèse , Prothèse valvulaire cardiaque , Remplacement valvulaire aortique par cathéter , Humains , Remplacement valvulaire aortique par cathéter/méthodes , Valve aortique/chirurgie , Prothèse valvulaire cardiaque/effets indésirables , Mâle , Sujet âgé , Défaillance de prothèse , Femelle , Sténose aortique/chirurgie , Implantation de valve prothétique cardiaque/méthodes , Complications postopératoires/étiologieSujet(s)
Sténose aortique , Remplacement valvulaire aortique par cathéter , Humains , Sténose aortique/chirurgie , Sténose aortique/physiopathologie , Remplacement valvulaire aortique par cathéter/effets indésirables , Remplacement valvulaire aortique par cathéter/méthodes , Résultat thérapeutique , Valve aortique/chirurgie , Valve aortique/imagerie diagnostique , Indice de gravité de la maladieRÉSUMÉ
Transcatheter aortic valve implantation (TAVI) is now utilised as a less invasive alternative to surgical aortic valve replacement (SAVR) across the whole spectrum of surgical risk. Long-term durability of the bioprosthetic valves has become a key goal of TAVI as this procedure is now considered for younger and lower-risk populations. The purpose of this article is to present a state-of-the-art overview on the definition, aetiology, risk factors, mechanisms, diagnosis, clinical impact, and management of bioprosthetic valve dysfunction (BVD) and failure (BVF) following TAVI with a comparative perspective versus SAVR. Structural valve deterioration (SVD) is the main factor limiting the durability of the bioprosthetic valves used for TAVI or SAVR, but non-structural BVD, such as prosthesis-patient mismatch and paravalvular regurgitation, as well as valve thrombosis or endocarditis may also lead to BVF. The incidence of BVF related to SVD or other causes is low (<5%) at midterm (5- to 8-year) follow-up and compares favourably with that of SAVR. The long-term follow-up data of randomised trials conducted with the first generations of transcatheter heart valves also suggest similar valve durability in TAVI versus SAVR at 10 years, but these trials suffer from major survivorship bias, and the long-term durability of TAVI will need to be confirmed by the analysis of the low-risk TAVI versus SAVR trials at 10 years.